These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21980765)

  • 61. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2021 Jan; 51(1):8-58. PubMed ID: 33897062
    [No Abstract]   [Full Text] [Related]  

  • 62. Nitazoxanide for chronic hepatitis C.
    Nikolova K; Gluud C; Grevstad B; Jakobsen JC
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
    [TBL] [Abstract][Full Text] [Related]  

  • 63. No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30 days course of nitazoxanide monotherapy.
    Laufer N; Abusamra L; Bolcic F; Gun A; Rolón MJ; Pérez H; Krolewiecki A; Salomón H; Quarleri J; Cahn P
    Antiviral Res; 2011 Dec; 92(3):497-9. PubMed ID: 22020160
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
    Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
    J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4.
    Kabil SM; Soliman MS; Youssef SM; Mounier BI
    J Egypt Soc Parasitol; 2011 Aug; 41(2):251-61. PubMed ID: 21980765
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
    Lee SS; Ferenci P
    Antivir Ther; 2008; 13 Suppl 1():9-16. PubMed ID: 18432158
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.
    Berg T; Carosi G
    Antivir Ther; 2008; 13 Suppl 1():17-22. PubMed ID: 18432159
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent.
    Shakya A; Bhat HR; Ghosh SK
    Curr Drug Discov Technol; 2018; 15(3):201-213. PubMed ID: 28748751
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.